INDONESIA
South-East Asia Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
Based on 2012 reported data
PP
no cases
80100
Based on 2012 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Insufficient data
Insufficient data
0
PP
Population
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
2014
Parasites and vectors
30000000
36500000
188000000
254500000
12
14
74
Major plasmodium species: P.falciparum (57%), P.vivax (43%)
Major anopheles species:
An. sundaicus, An. balabacensis, An. maculatus, An. farauti, An. subpictus, An. subpictus
Programme phase:
Control
Reported confirmed cases:
252027 Estimated cases, 2013: [32000005300000]
Reported confirmed cases at community level:
0
Reported deaths:
64 Estimated deaths, 2013:
[54012000]
II. Intervention policies and strategies
Intervention Policies/strategies
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2004
ITNs/LLINs distributed to all age groups
Yes
2004
IRS
IRS is recommended
Yes
1959
DDT is authorized for IRS
No
Larval control Use of larval control recommended
Yes
1990
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2007
Malaria diagnosis is free of charge in the public sector
Yes
1959
Treatment ACT is free for all ages in public sector
Yes
2004
Sale of oral artemisinin-based monotherapies
Never allowed 2010
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2004
Primaquine is used for radical treatment of P.vivax
Yes 2004
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
Surveillance ACD for case investigation (reactive)
Yes
1965
ACD of febrile cases at community level (pro-active)
Yes
1965
Mass screening is undertaken
Yes
1965
Uncomplicated P.falciparum cases routinely admitted
Yes
1990
Uncomplicated P.vivax cases routinely admitted
Yes
1990
USAID/PMI
WHO/UNICEF
Source: DHS 2007
Cases per 1000
100
80
60
40
20
0
Management and other costs
Source: DHS 2012
Human Resources & technical Assistance
Monitoring and evaluation
Antimalarial medicines
Diagnostics
2000 2001 2002 2003 2004 2005 2006
2007 2008 2009 2010 2011 2012 2013 2014
ITNs
Suspected cases tested
Antimalarials distributed vs reported cases
Insecticide & spraying materials
<5 with fever with finger/heel stick (survey)
ACTs distributed vs reported P. f. cases
Primaquine distributed vs reported P. v. cases
ACTs as % of all antimalarials received by <5 (survey)
All ages who slept under an ITN (survey)
At high risk protected with IRS
At high risk protected with ITNs
All ages who slept under an ITN (survey)
Cases
Households
withtracked
at least one ITN
At high risk protected with IRS Points
At high risk protected with IRS
Source: DHS 2003, DHS 2007, DHS 2012
Tests (%)
Test positivity
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Reporting completeness
Suspected cases tested
<5 with fever with finger/heel stick (survey)
ACTs as % of all antimalarials received by <5
Primaquine distributed vs reported P.v cases points
Primaquine distributed vs reported P.v cases
ACTs distributed vs reported P.f cases points
ACTs distributed vs reported P.f cases
distributed
reported
cases 2010
points 2011 2012 2013 2014
2000 2001 2002 2003 2004Antimalarials
2005 2006
2007 vs2008
2009
distributedrate
vs reported cases RDT positivity rate
Parasite prevalence (survey) Antimalarials
Slide positivity
Estimated cases detected - top
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
ABER (microscopy & RDT)
Cases (all species)
Funding source(s): Government,
Global Fund, WHO, UNICEF
Cases tested and treated in public sector
% fever cases <5 seeking treatment at public HF (survey)
10
8
6
4
2
0
Pie chart includes 100%
of total contributions
Others
Cases (%)
Population (%)
(%)
Organophosphate Species/complex tested
No
An. subpictus s.l., An. sundaicus
s.l., other
Insecticides & spray materials
ITNs
Diagnostic testing
Antimalarial medicines
Monitoring and evaluation
Human resources & technical assistance
Management and other costs
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Pyrethroid DDT Carbamate
Yes
No
Yes
Financing by intervention in 2014
ITN and IRS coverage
Others
WHO_UNICEF
USAID/PMI
Worldbank (USD)
Global Fund (USD)
Malaria budget (USD)
At high risk protected with ITNs
Households with at least one ITN
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20112014
Cases (P. vivax)
Malaria admissions and deaths
5
4
3
2
1
0
500 000
400 000
300 000
200 000
100 000
0
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Admissions (all species)
Deaths (all species)
1000
800
600
400
200
0
Deaths
World Bank
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
Adopted
DHA-PP+PQ
2008
QN+D+PQ 2004
AM; AS; QN
2004
AS+AQ; DHA-PP+PQ(14d)
2008
0.25 mg/kg (14 d)
P.f + all species (Combo).
Therapeutic efficacy tests (clinical and parasitological failure, %)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
First-line treatment of unconfirmed malaria
First-line treatment of P.falciparum
Treatment failure of P.falciparum
Treatment of severe malaria
Treatment of P.vivax
Dosage of primaquine for radical treatment of P.vivax
Type of RDT used
Admissions
60
48
36
24
12
0
ABER (%)
Contribution (US$m)
III. Financing
Antimalaria treatment policy
Admissions (P. vivax)
Deaths (P. vivax)
Impact: Insufficiently consistent data to assess trends
Aber (microscopy
& RDT)
Cases
(p.vivax) points
Admissions (P.vivax) points
Cases (p.vivax)
Admissions (P.vivax)
Cases (all species) points
Admissions (all species) points
Cases (all species)
Admissions (all species)
Deaths (P.vivax) points
Deaths (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species) points
Deaths (all species)
127
